Skip to main content

Table 3 Relation between tumor response and metabolic toxicities

From: Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

  CTC Grade of Toxicities Highest change in biological parameters Median time to CTC Grade ≥ 2 toxicities
CB (%) / PD (%) (p) CB (%) / PD (%) (p) CB (days) / PD (days)
Lymphopenia    NA / 84 (0.01)
Increase in serum creatinine 92 / 46 (0.01) +61 / -5 (0.002)  
Hyperglycemia    56/112 (0.03)
Hypophosphatemia   −26 / -9 (0.02)  
Increase in ASAT 94 / 66 (0.04) +126 / +8 (0.004)  
Increase in ALAT 100 / 66 (0.01) +229 / +4 (0.003)  
Hypercholesterolemia    
Hypertriglyceridemia    
  1. CB Clinical Benefit, PD Progressive Disease, NA not attained